INMB Stock Summary and Trading Ideas (Inmune Bio | NASDAQ:INMB)

INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.

Inmune Bio trades on the NASDAQ stock market under the symbol INMB.

As of April 23, 2024, INMB stock price declined to $10.14 with 169,090 million shares trading.

INMB has a beta of 1.17, meaning it tends to be more sensitive to market movements. INMB has a correlation of 0.05 to the broad based SPY ETF.

INMB has a market cap of $184.58 million. This is considered a Micro Cap stock.

Last quarter Inmune Bio reported $28,000 in Revenue and -$.47 earnings per share. This fell short of revenue expectation by $-12,000 and missed earnings estimates by -$.03.

In the last 3 years, INMB stock traded as high as $30.37 and as low as $4.63.

The top ETF exchange traded funds that INMB belongs to (by Net Assets): VTI, VXF, ONEQ, IWC, AVSC.

INMB has outperformed the market in the last year with a price return of +38.0% while the SPY ETF gained +24.3%. However, in the short term, INMB had mixed performance relative to the market. It has underperformed in the last 3 months, returning -9.2% vs +4.9% return in SPY. But in the last 2 weeks, INMB shares have fared better than the market returning -2.1% compared to SPY -2.5%.

INMB support price is $10.04 and resistance is $11.21 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INMB stock will trade within this expected range on the day.